152 related articles for article (PubMed ID: 37351507)
1. Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial.
Osonoi T; Shirabe S; Saito M; Hosoya M; Douguchi S; Ofuchi K; Katoh M
Front Pharmacol; 2023; 14():1205021. PubMed ID: 37351507
[No Abstract] [Full Text] [Related]
2. Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Nomoto H; Takahashi A; Nakamura A; Kurihara H; Takeuchi J; Nagai S; Taneda S; Miya A; Kameda H; Cho KY; Miyoshi H; Atsumi T
BMJ Open Diabetes Res Care; 2022 Nov; 10(6):. PubMed ID: 36379585
[TBL] [Abstract][Full Text] [Related]
3. The Effects of Imeglimin on the Daily Glycemic Profile Evaluated by Intermittently Scanned Continuous Glucose Monitoring: Retrospective, Single-Center, Observational Study.
Oda T; Satoh M; Nagasawa K; Sasaki A; Hasegawa Y; Takebe N; Ishigaki Y
Diabetes Ther; 2022 Sep; 13(9):1635-1643. PubMed ID: 35895275
[TBL] [Abstract][Full Text] [Related]
4. Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study).
Nomoto H; Oba-Yamamoto C; Takahashi Y; Takeuchi J; Nagai S; Yokoyama H; Taneda S; Kurihara Y; Aoki S; Kameda H; Cho KY; Nakamura A; Atsumi T; Miyoshi H
Diabetes Ther; 2021 Mar; 12(3):955-964. PubMed ID: 33491111
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.
Reilhac C; Dubourg J; Thang C; Grouin JM; Fouqueray P; Watada H
Diabetes Obes Metab; 2022 May; 24(5):838-848. PubMed ID: 34984815
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
Dubourg J; Fouqueray P; Quinslot D; Grouin JM; Kaku K
Diabetes Obes Metab; 2022 Apr; 24(4):609-619. PubMed ID: 34866306
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of imeglimin for the treatment of type 2 diabetes.
Johansson KS; Brønden A; Knop FK; Christensen MB
Expert Opin Pharmacother; 2020 Jun; 21(8):871-882. PubMed ID: 32108532
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trials.
Singh AK; Singh A; Singh R; Misra A
Diabetes Metab Syndr; 2023 Feb; 17(2):102710. PubMed ID: 36702046
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials.
Abdelhaleem IA; Salamah HM; Alsabbagh FA; Eid AM; Hussien HM; Mohamed NI; Ebada MA
Diabetes Metab Syndr; 2021; 15(6):102323. PubMed ID: 34717136
[TBL] [Abstract][Full Text] [Related]
10. Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study.
Uchida T; Ueno H; Konagata A; Taniguchi N; Kogo F; Nagatomo Y; Shimizu K; Yamaguchi H; Shimoda K
Diabetes Ther; 2023 Mar; 14(3):569-579. PubMed ID: 36732433
[TBL] [Abstract][Full Text] [Related]
11. Imeglimin-mediated glycemic control in maternally inherited deafness and diabetes.
Ishibashi R; Hirayama K; Watanabe S; Okano K; Kuroda Y; Baba Y; Kanayama T; Ito C; Kasahara K; Aiba S; Iga R; Ohtani R; Inaba Y; Koshizaka M; Maezawa Y; Yokote K
J Diabetes Investig; 2023 Dec; 14(12):1419-1422. PubMed ID: 37715448
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.
Theurey P; Thang C; Pirags V; Mari A; Pacini G; Bolze S; Hallakou-Bozec S; Fouqueray P
Endocrinol Diabetes Metab; 2022 Nov; 5(6):e371. PubMed ID: 36239048
[TBL] [Abstract][Full Text] [Related]
13. Hemolysis causes a decrease in HbA1c level but not in glycated albumin or 1,5-anhydroglucitol level.
Kiniwa N; Okumiya T; Tokuhiro S; Matsumura Y; Matsui H; Koga M
Scand J Clin Lab Invest; 2019 Oct; 79(6):377-380. PubMed ID: 31204512
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.
Dubourg J; Fouqueray P; Thang C; Grouin JM; Ueki K
Diabetes Care; 2021 Apr; 44(4):952-959. PubMed ID: 33574125
[TBL] [Abstract][Full Text] [Related]
15. Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes.
Chan CL; Pyle L; Kelsey MM; Newnes L; Baumgartner A; Zeitler PS; Nadeau KJ
Pediatr Diabetes; 2017 Nov; 18(7):629-636. PubMed ID: 27873436
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of imeglimin in patients with type 2 diabetes: A retrospective longitudinal study in Japan.
Katsuyama H; Hakoshima M; Heshiki T; Iida S; Adachi H; Yanai H
Diabetes Res Clin Pract; 2024 Jun; 213():111752. PubMed ID: 38908549
[TBL] [Abstract][Full Text] [Related]
17. Imeglimin Improved Plasma Glucose Levels in Patients With Latent Autoimmune Diabetes of Adults: Report of 2 Cases.
Okada S; Okada K; Okada J; Yamada E
JCEM Case Rep; 2024 Jan; 2(1):luad161. PubMed ID: 38116160
[TBL] [Abstract][Full Text] [Related]
18. Beyond HbA1c.
Bloomgarden Z
J Diabetes; 2017 Dec; 9(12):1052-1053. PubMed ID: 28792665
[TBL] [Abstract][Full Text] [Related]
19. Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study.
Matsuhisa M; Miyoshi H; Yabe D; Takahashi Y; Morimoto Y; Terauchi Y
Diabetes Ther; 2023 Jan; 14(1):219-236. PubMed ID: 36422802
[TBL] [Abstract][Full Text] [Related]
20. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
